Barclays Maintains an 'Equalweight' on Warner Chilcott (WCRX); Balance Hangs on Loestrin

Barclays maintains an 'Equalweight' on Warner Chilcott (NASDAQ: WCRX) price target of $18.00.

Analyst, Douglas D. Tsao, said, "We are adjusting our EPS estimates for WCRX ahead of the company's 4Q EPS report on Friday: While WCRX's valuation remains attractive on an EPS basis at just 4.5x our FY12E adjusted EPS of $3.64 (from $3.89), we remain on the sidelines, as we are not sure this is the appropriate valuation framework since WCRX's EV/EBITDA multiple is less attractive at 6x. WCRX must still address the sustainability of its franchise given the loss of exclusivity on key products, most notably Loestrin in 2014."

For an analyst ratings summary and ratings history on Warner Chilcott click here. For more ratings news on Warner Chilcott click here.

Shares of Warner Chilcott closed at $16.47 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• UBS Reiterates Buy Rating on HF Sinclair (DINO)